No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LAB Standard BioTools
- 2.050
- -0.060-2.84%
Close Jun 18 16:00 ET
- 2.090
- +0.040+1.95%
Post 17:25 ET
758.34MMarket Cap-2050P/E (TTM)
2.120High2.040Low1.82MVolume2.100Open2.110Pre Close3.80MTurnover0.76%Turnover RatioLossP/E (Static)369.92MShares3.16052wk High1.31P/B493.10MFloat Cap1.57052wk Low--Dividend TTM240.54MShs Float49.455Historical High--Div YieldTTM3.79%Amplitude0.920Historical Low2.084Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Standard BioTools(LAB.US) 10% Shareholder Buys US$260K in Common Stock
$Standard BioTools(LAB.US)$ 10% Shareholder Casdin Partners Master Fund, L.P. purchased 100K shares of common stock on May 23, 2024 at an average price of $2.6 for a total value of $260K. This transac
Express News | Standard BioTools Purchases The Carterra LSA-XT System; No Financial Terms Disclosed
Express News | Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Standard BioTools(LAB.US) 10% Shareholder Buys US$1.54 Million in Common Stock
$Standard BioTools(LAB.US)$ 10% Shareholder Casdin Partners Master Fund, L.P. purchased 600K shares of common stock on May 20, 21, 22, 2024 at an average price of $2.5697 for a total value of $1.54 mi
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools") (NASDAQ:LAB) today announced that its management team will participate in the following investor conferences in
Comments
$Standard BioTools(LAB.US$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers
5
$Standard BioTools(LAB.US$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
$Standard BioTools(LAB.US$ Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
3
$Standard BioTools (LAB.US)$ This is 22% shorted should squeeze nicely tomorrow
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg